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SHARPIN-deficient mice display a multiorgan
chronic inflammatory phenotype suggestive of
altered leukocyte migration. We therefore studied
the role of SHARPIN in lymphocyte adhesion, polari-
zation, and migration. We found that SHARPIN local-
izes to the trailing edges (uropods) of both mouse
and human chemokine-activated lymphocytes
migrating on intercellular adhesion molecule-1
(ICAM-1), which is one of the major endothelial
ligands for migrating leukocytes. SHARPIN-deficient
cells adhere better to ICAM-1 and show highly elon-
gated tails whenmigrating. The increased tail lifetime
in SHARPIN-deficient lymphocytes decreases the
migration velocity. The adhesion, migration, and
uropod defects in SHARPIN-deficient lymphocytes
were rescued by reintroducing SHARPIN into the
cells. Mechanistically, we show that SHARPIN inter-
acts directly with lymphocyte-function-associated
antigen-1 (LFA-1), a leukocyte counterreceptor for
ICAM-1, and inhibits the expression of intermediate
and high-affinity forms of LFA-1. Thus, SHARPIN
controls lymphocyte migration by endogenously
maintaining LFA-1 inactive to allow adjustable
detachment of the uropods in polarized cells.INTRODUCTION
SHARPIN is a widely expressed cytosolic protein that, together
with HOIL-1L interacting protein and HOIL-1L, forms the linearCeubiquitin chain assembly complex (LUBAC) (Gerlach et al.,
2011; Ikeda et al., 2011; Tokunaga et al., 2011). The ternary
LUBAC complex catalyzes the formation of linear polyubiquitin
chains, which regulate cell signaling, most notably the canonical
nuclear factor (NF)-kB activation in response to stimuli like tumor
necrosis factor (TNF).
A spontaneous SHARPIN-null mutation in Sharpincpdm mice
manifests with a progressive multiorgan inflammatory pheno-
type (HogenEsch et al., 1993; Seymour et al., 2007). The most
prominent feature in thesemice is chronic proliferative dermatitis
resembling psoriasis, but the mice also display leukocytosis,
inflammation in many other organs (gastrointestinal track, liver,
etc.), splenomegaly, abnormal development of Peyer’s patches,
hypoimmunoglobulinemia, and defective Th1 cytokine produc-
tion. The complex Sharpincpdm phenotype is partially linked to
signaling and cytokine defects. Thus, the skin inflammation
can be reversed by crossing Sharpincpdm mice with TNF-
deficient mice (Gerlach et al., 2011). This is thought to be due
to elimination of the increased LUBAC-dependent cell-death
sensitivity of Sharpincpdm keratinocytes upon TNF triggering
and subsequent alleviation of secondary inflammatory response.
Sharpincpdm mice also have decreased secretion of proinflam-
matory cytokines (e.g., interferon-g, interleukin [IL]-6, and
IL-12) and increased secretion of Th2-type cytokines (IL-5;
Renninger et al., 2010; Wang et al., 2012; Zak et al., 2011).
However, the noncutaneous lymphoid aberrations are not
affected by TNF elimination (Gerlach et al., 2011), mice deficient
for HOIL-1 (another LUBAC component) do not appear to display
any overt inflammatory phenotype (Tokunaga et al., 2009), and
pharmacological inhibition of NF-kB signaling only partially
alleviates the skin inflammation (Liang et al., 2011). Moreover,
although blockade of IL-5 virtually eliminates eosinophils from
Sharpincpdm mice, it does not affect the inflammation phenotype
(Renninger et al., 2010). It is therefore tempting to speculatell Reports 5, 619–628, November 14, 2013 ª2013 The Authors 619
Figure 1. SHARPIN Regulates Uropod Detachment in Migrating Lymphocytes
(A) CXCL12-stimulated, wild-type, andSharpin-deficient (Sharpincpdm)mouse splenocytesmigrating on recombinant mouse ICAM-1 (5 mg/ml) immunostained for
SHARPIN and CD44. Representative micrographs and quantitation of mean fluorescence intensities (MFI) along the cell axis (mean ± SEM [SEM in gray color];
n > 10 cells/staining; statistical comparisons between the 20 first frontal and 20 last posterior measurement points) are shown. The scale bars represent 10 mm.
(legend continued on next page)
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that other, non-LUBAC-dependent functions of SHARPIN con-
tribute to the dysregulated leukocyte accumulation seen in
Sharpincpdm mice.
Chemokine-triggered leukocyte migration on endothelial cells
is one crucial step during the leukocyte traffic into sites of inflam-
mation (Ley et al., 2007; Vestweber, 2012). Given that SHARPIN
has previously been reported to inhibit b1-integrins in cancer
cells (Rantala et al., 2011), we asked whether SHARPIN could
regulate leukocyte locomotion in inflammation. Here, we
observed that SHARPIN strongly localizes to the trailing edges
(called uropods in leukocytes) of migrating lymphocytes and
controls uropod detachment and cell locomotion. In migrating
lymphocytes, the leading edge and the midcell zone are thought
to display active lymphocyte-function-associated antigen-1
(LFA-1, a heterodimeric aLb2-integrin expressed on practically
all leukocytes) capable of binding to intercellular adhesion
molecule-1 (ICAM-1) and other ligands. Uropods, in contrast,
express inactive LFA-1, which facilitates cellular detachment
(Morin et al., 2008; Smith et al., 2005; Stanley et al., 2008).
However, the mechanisms of uropodial LFA-1 deactivation
have remained unknown. We now show that SHARPIN regulates
lymphocyte polarity by directly interacting and deactivating
LFA-1. Thus, our data reveal SHARPIN as a regulator of uropod
detachment, which is the final checkpoint in leukocyte extrava-
sation, and suggest a mechanism that dynamically controls
deactivation of leukocyte integrins.
RESULTS
Impaired Uropod Detachment in SHARPIN-Deficient
Lymphocytes
SHARPIN-deficient Sharpincpdm mice manifest with aberrant
leukocyte infiltrations in many organs, and therefore, we studied
whether SHARPIN would play a role in leukocyte locomotion.
We found that endogenous SHARPIN is preferentially localized
to the detached uropods, together with an established
uropod marker CD44, in chemokine C-X-C-motif ligand 12
(CXCL12) -activated wild-type splenocytes migrating on recom-
binant mouse ICAM-1 (Figure 1A). Sharpincpdm splenocytes,
which, as expected, lacked anti-mouse SHARPIN antibody reac-
tivity, were flatter and displayed a loss of distinctive uropod
structures, showing instead elongated trailing edges adherent
to the substrate.
SHARPIN-deficient splenocytes and thymocytes adhered to
and spread on ICAM-1 significantly better than wild-type cells
(Figures 1B and 1C). Furthermore, lymphocyte migration
on ICAM-1 was regulated by SHARPIN in a substrate-
concentration-dependent manner (Figure 1D). When low levels(B and C) Adhesion (B) and spreading (C) of wild-type and Sharpincpdm splenocy
(D and E) Migration of CXCL12-stimulated, wild-type, and Sharpincpdm (D) sple
Representative cell tracks and cumulative data are shown. See also Movies S1 a
(F) Phenotype of the uropods in cells migrating on high ICAM-1 concentration (
uropod length >33% of cell body diameter, polarity index is the ratio of the longes
uropod lifetime is the time difference between uropod appearance and disappea
(G) Expression of SHARPIN, CD44, F-actin, and talin in purified, CXCL12-sti
concentration (50 mg/ml). Representative micrographs and quantitations as in (A
Data are representative from or are the mean ± SEM of three (A–D and F) and two (
the uropods/tails. The asterisk denotes p < 0.05, double asterisks denote p < 0.
Ceof ICAM-1 substrate (0.5–5 mg/ml) were used, CXCL12-
stimulated Sharpincpdm lymphocytes migrated significantly
faster than wild-type cells. However, at a high ICAM-1 concen-
tration (50 mg/ml), SHARPIN-deficient lymphocytes migrated
much slower than the wild-type cells. Purified CD4+ T cells
from Sharpincpdm mice also migrated faster on low ICAM-1
concentration and slower on high ICAM-1 concentration than
purified wild-type CD4+ cells (Figure 1E; Movie S1). Sharpincpdm
cells migrating on high ICAM-1 concentration had more
extended tails than wild-type cells and showed an abnormally
strongly polarized morphology (Figure 1F). Moreover, the uro-
pod/tail lifetime was significantly longer for lymphocytes lacking
SHARPIN, and consequently, the SHARPIN-deficient cells
showed impaired detachment from the matrix (Figure 1F;
Movie S2). Wild-type cells migrating on high ICAM-1 concen-
tration (50 mg/ml) showed preferential localization of SHARPIN
and CD44 to uropods and phalloidin staining revealed typical
cortical F-actin enriched in the uropods, whereas talin (an
integrin activator normally polarized to the cell front [Go´mez-
Mo´uton et al., 2001]) accumulated at the leading edges
(Figure 1G). In Sharpincpdm cells, in contrast, CD44 and talin
both distributed more evenly throughout the cells, and the
strongly elongated tails were positive for filamentous actin
throughout the tails.
Lymphocytes bind to ICAM-1 mainly via LFA-1 (Hogg et al.,
2011). Integrin-mediated cell migration is dependent on receptor
expression levels, receptor activity, and ligand density (following
a bell-shaped curve), and detachment of trailing edges of
cells requires disassembly of integrin-containing adhesions
(Constantin et al., 2000; Franco et al., 2004; Palecek et al.,
1997). Therefore, the increased migration speed on low
ICAM-1 concentration and the elongated tails on high ICAM-1
concentration in Sharpincpdm lymphocytes could be indicative
of higher LFA-1 expression levels or activity. We found that
aLb2 (LFA-1) integrin was expressed on practically all thymo-
cytes and splenocytes (92%–95%; n = 7–8 mice/group) of
both wild-type and Sharpincpdm mice, and the levels were com-
parable (thymocytes and CD4+ splenocytes) or slightly lower
(total splenocytes) on Sharpincpdm cells (Figures 2A and 2B).
The expression of other integrins (aM/CD11b, aX/CD11c, and
a4/CD49d) and the numbers of CD4+ and CD8+ T cells, B220+
B cells, CD4+CD25+FoxP3+ T regulatory cells, and cells
expressing chemokine receptors (CXCR4, CCR7, and CCR9)
and activation markers (CD25 and L-selectin) were also similar
in spleen and thymus of wild-type and Sharpincpdm mice, with
the exception of minor changes in the numbers of CD4+ cells
and CD49d-positive cells among total splenocytes (Figures
S1A–S1F; data not shown). Notably, among CD4+ splenocytes,tes and thymocytes on ICAM-1 (5 mg/ml).
nocytes and (E) purified CD4+ T cells on different concentrations of ICAM-1.
nd S2.
50 mg/ml) was determined using image analyses. Extended uropod defines a
t leading-edge-to-uropod distance divided by the longest width of the cell, and
rance. The scale bars represent 10 mm.
mulated CD4+ wild-type, and Sharpincpdm cells migrating on high ICAM-1
) (n = 5–8 cells/staining) are shown. The scale bars represent 10 mm.
E and G) independent experiments. In (A), (F), and (G), the white arrows point to
01, and triple asterisks denote p < 0.001 (two-tailed Student’s t test).
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Figure 2. SHARPIN and Inactive LFA-1 Colocalize in Uropods
(A and B) Expression of LFA-1 on isolated wild-type and Sharpincpdm thymocytes and total and CD4-positive splenocytes. Shown are (A) representative FACS
plots and (B) the specific mean fluorescence intensities (MFI) ± SEM for CD11a.
(C) Immunostainings of cytospin preparations of resting human PBMCwith SHARPIN and control antibodies. DAPI was used to visualize nuclear morphology. An
arrowhead points to a representative lymphocyte. The scale bars represent 10 mm.
(D) Immunostainings of freshly isolated, CXCL12-stimulated human PBMCmigrating on recombinant human ICAM-1 (5 mg/ml) for SHARPIN (a nonpolarized and
polarized cell are shown).
(E and F) Immunostainings of GFP-SHARPIN-transfected, CXCL12-stimulated human PBMC migrating on ICAM for (E) CD44 and (F) talin.
(G–I) Immunostainings of freshly isolated, CXCL12-stimulated human PBMC migrating on ICAM-1 for SHARPIN and (G) CD11a (total), (H) extended LFA-1
(KIM127 epitope), and (I) activated LFA-1 (24 epitope).
(J) Quantitations of mean fluorescence intensities (MFI) of the indicated stainings along the cell axis (mean ± SEM [SEM in gray color]; n > 4–8 cells/staining;
statistical comparisons between the 20 first frontal and 20 last posterior measurement points) are shown.
In (D)–(I), the white arrows point to the uropods and the bars are 5 mm.Data in (A) and (B) are from four to ninemice/genotype and in (C)–(I) representative of at least
three independent experiments with different blood cell donors. The asterisk denotes p < 0.05, double asterisks denote p < 0.01, and triple asterisks denote
p < 0.001 (two-tailed Student’s t test). See also Figure S1.
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the expression of aM/CD11b and CD49d was similar in both
genotypes. Together, these data show that the lymphocyte phe-
notypes of wild-type and Sharpincpdm lymphocytes are relatively
similar and that SHARPIN preferentially localizes to uropods in
migrating lymphocytes and regulates uropod stability, adhesion
to the substrate, and migration velocity both in total splenocytes
and purified CD4+ T cells.
SHARPIN Preferentially Colocalizes with Inactive LFA-1
in Uropods
To analyze the possible role of SHARPIN in regulating LFA-1
activity, we used human cells, for which reporter antibodies for
LFA-1 activity are available. In freshly isolated human peripheral
blood mononuclear cells (PBMCs) and in CXCL12-stimulated
PBMC binding to recombinant ICAM-1, stainings with specific
SHARPIN antibodies (Figures S1G and S1H) showed SHARPIN
to be evenly distributed in the cytoplasm of nonpolarized cells
(Figures 2C and 2D). In contrast, in polarized cells (>100 cells
analyzed) endogenous SHARPIN was always concentrated in,
but not restricted to, the uropods (Figures 2D and S1I). GFP-
SHARPIN transfected into PBMC also preferentially localized in
CD44-positive uropods and was less abundant in the talin-
positive leading edges (Figures 2E and 2F). Leukocytes
migrating in a lymphoid tissue in vivo also showed enrichment
of endogenous SHARPIN in the uropods (Figure S3J).
In human cells migrating on ICAM-1, LFA-1 was found both at
the leading edge and in the uropod, and endogenous SHARPIN
(as well as GFP-SHARPIN) and LFA-1 partially colocalized in the
uropods (Figures 2G, S1K, and S1L). KIM127 and 24 are unique
reporter monoclonal antibodies (mAbs), which specifically
detect the extended, intermediate-affinity, and high-affinity
forms of LFA-1, respectively (Dransfield and Hogg, 1989; Hogg
et al., 2011; Robinson et al., 1992). On freshly isolated, migrating
PBMC, the KIM127 and 24 signals concentrated to the leading
edge and midcell zones, whereas SHARPIN mainly localized to
the uropod (Figures 2H and 2I). Thus, our quantitative data
(Figure 2J) show that SHARPIN is enriched in uropods together
with inactive LFA-1 in contrast to the integrin activator talin and
active LFA-1, which mainly localize to the leading edge and
midcell zones.
SHARPIN Interacts with LFA-1
SHARPIN has been shown to physically interact with CD29 cell
adhesion receptors in cancer cells (Rantala et al., 2011). To study
whether SHARPIN can physically interact with leukocyte
integrins, we cotransfected plasmids encoding aL and b2 chains
of LFA-1 with GFP-SHARPIN (or GFP only as a control) into
human embryonic kidney 293 (HEK293) cells. An aL antibody
specifically coimmunoprecipitated GFP-SHARPIN, but not
GFP (Figure 3A). Endogenous LFA-1 and endogenous SHARPIN
from Jurkat cells and freshly isolated human PBMC also
coimmunoprecipitated. LFA-1 was also detected in reciprocal
immunoprecipitations with SHARPIN antibody (Figures 3B and
3C). Activation of PBMC for 2–30 min with CXCL12 did not alter
the protein levels of SHARPIN or LFA-1 (Figure S2).
Purified recombinant full-length LFA-1, but not LFA-1 protein
lacking the cytoplasmic domains, bound to recombinant GST-
SHARPIN, but not GST alone, in pull-down assays (Figures 3DCeand 3E). Far-western analyses confirmed this interaction (Fig-
ure 3F). The full-length cytoplasmic sequence of aL, but not of
b2, and the conserved membrane proximal part of the aL-tail
synthesized as biotinylated peptides bound to GFP-SHARPIN
from cell lysates (Figure 3G). The cytoplasmic sequences of
other leukocyte integrins aM and aD (aX was insoluble) also
interactedwithGFP-SHARPIN (Figure 3G). All these experiments
clearly show that SHARPIN directly binds to the cytoplasmic
domain of aL.
SHARPIN Maintains LFA-1 in an Inactive Conformation
and Regulates Lymphocyte Extravasation
Direct interaction between SHARPIN and LFA-1 and the colocal-
ization of inactive LFA-1 and SHARPIN in the uropods led us to
study whether SHARPIN could be involved in LFA-1 inactivation.
Knockdown of SHARPIN in human PBMC (on average
50%–70%) increased the adhesion of these cells to human
recombinant ICAM-1, improved their migration on low ICAM-1
concentration, and inhibited their migration on high ICAM-1 con-
centration (Figures 4A and 4B). Conversely, overexpression of
SHARPIN significantly reduced the expression of the LFA-1 acti-
vation epitopes KIM127 and 24 on cultured, CXCL12-stimulated
PBMC in fluorescence-activated cell sorting (FACS) analyses
(Figures 4C and S3A). Moreover, transiently expressed human
LFA-1 was more active in Sharpincpdm mouse embryonic fibro-
blasts (MEFs) than in wild-type MEFs (Figures 4D and S3B).
These functional data show that SHARPIN inhibits LFA-1.
To study the role of SHARPIN in lymphocyte migration in vivo,
we performed competitive homing assays, in which the ability of
lymphocytes to move from the blood through the vessel wall into
the tissue is measured. Splenocytes from wild-type and
Sharpincpdmmice were isolated, labeled with two different inten-
sities of a fluorescent dye (carboxyfluorescein succinimidyl ester
[CFSE]) and injected intravenously into wild-type recipients.
After a 2 hr recirculation period, Sharpincpdm lymphocytes
(both total splenocytes and CD4+ lymphocytes) homed to
peripheral (PLN) and mesenteric (MLN) lymph nodes with about
half the efficiency of their wild-type counterparts (sevenmice per
group; Figures 4E and 4F). In an independent experiment, the
reduced lymph node homing of Sharpincpdm splenocytes and
CD4+ T cells was confirmed and we observed that, instead,
Sharpincpdm cells accumulated more in the spleen than wild-
type cells (Figure S3C). Also, in microscopic analyses, fewer
Sharpincpdm lymphocytes accumulated in PLN parenchyma
than wild-type cells 30 min after intravenous transfer (Figure 4G).
Thus, absence of SHARPIN impairs lymphocyte homing to
lymph nodes.
The function of SHARPIN in lymphocyte transmigration was
studied using time-lapse microscopy in in vitro flow chamber
assays, in which human PBMCs are perfused with a defined
shear stress over cultured confluent endothelial monolayers.
After adhesion, control small interfering RNA (siRNA)-silenced
human PBMC transmigrated (transition from white/gray to black
cells in phase contrast images) through the endothelium prefer-
entially at the endothelial cell junctions. SHARPIN localized to the
uropods during the transmigration (Figure 4H). After comple-
tion of the transmigration, the majority of cells swiftly moved
onward from the transmigration site (Figure 4I; Movie S3).ll Reports 5, 619–628, November 14, 2013 ª2013 The Authors 623
Figure 3. SHARPIN Directly Binds to the Conserved Membrane Proximal Sequence of aL
(A–C) Coimmunoprecipitation of SHARPIN with LFA-1 in (A) HEK293 cells overexpressing aL and b2 integrins and GFP or GFP-SHARPIN, (B) Jurkat cells
(endogenous proteins), and (C) freshly isolated PBMC (endogenous proteins). IgG, immunoglobulin G; IP, immunoprecipitation.
(D) The integrin constructs used in the binding studies (ECD, extracellular domain; TMD, transmembrane domain; and CYPD, cytoplasmic domain) and the
sequences of the transmembrane and intracellular domains of aL, aM, aX, aD, and b2 integrins. The conserved membrane proximal area in a-tails is highlighted
in red.
(E) Pull-down experiments with recombinant GST-SHARPIN and recombinant full-length LFA-1 and LFA-1 lacking the cytoplasmic tails. GST only is a loading
control.
(F) Interaction of GST-SHARPIN or GST alone with the full-length and tailless LFA-1 heterodimers was determined using far-western overlay assays.
(G) Pull-down assays with synthetic biotinylated peptides corresponding to the cytoplasmic sequences of aL, aM, aD, and b2 with lysates of GFP-SHARPIN-
transfected cells. aL cons, the conserved membrane proximal part of aL.
Data are representative of at least three independent experiments. See also Figure S2.SHARPIN-silenced cells transmigrated with similar kinetics, but
thereafter they migrated less persistently away from the
transmigration sites and often had to make repetitive efforts to
leave the transmigration spot below the endothelium (Figure 4I;
Movie S3).
SHARPIN Rescues Migration and Uropod Detachment
Defects of SHARPIN-Deficient Cells
Sharpincpdm splenocytes expressing GFP-SHARPIN bound 60%
less to ICAM-1 (5 mg/ml) than Sharpincpdm splenocytes express-
ing GFP only (Figure 4J), showing that the increased adhesion of
Sharpincpdm cells on ICAM-1 was SHARPIN-dependent. Binding
of Sharpincpdm splenocytes to a non-integrin-dependent ligand
(poly-L-lysine) was not affected by SHARPIN.
The migration velocity of GFP-expressing Sharpincpdm lym-
phocytes on ICAM-1 (5 mg/ml) was significantly higher than
that of GFP-expressing wild-type cells (Figure 4K). Importantly,624 Cell Reports 5, 619–628, November 14, 2013 ª2013 The Authorsoverexpression of GFP-SHARPIN in Sharpincpdm cells reduced
the migration velocity significantly by 60% compared to GFP
only. In fact, wild-type and Sharpincpdm cells overexpressing
SHARPIN had comparable migration velocities. Moreover,
expression of GFP-SHARPIN, but not GFP alone, in Sharpincpdm
cells decreased the number of cells with uropods (Figure 4L).
Thus, SHARPIN is causally involved in regulating uropod forma-
tion, polarization, and lymphocyte motility on ICAM-1.
DISCUSSION
This study identifies a function for SHARPIN in regulating cell
polarization and uropod detachment in migrating lymphocytes.
We also describe SHARPIN as the first endogenous molecule
capable of inhibiting LFA-1 by binding directly to the integrin
a-tail. These data show that the inactive LFA-1 conformation is
not merely a passive default state in the leukocytes but
is actively maintained through adjustable intracellular protein
interactions.
Increased LFA-1 activation epitopes associated with lack of
SHARPIN expression and diminished LFA-1 activation with
increased SHARPIN expression. Because SHARPIN did not alter
LFA-1 expression levels, these data directly implicate SHARPIN
in regulation of LFA-1 activity. Because there is always a
dynamic balance between active and inactive LFA-1 on the cell
membrane, SHARPIN could help tomaintain LFA-1 in an inactive
conformation by preventing activation and/or by deactivating the
active conformation. Thus, in nonadherent and freshly adherent
cells, which do not have uropods and which display even
localization of SHARPIN throughout the cytoplasm, SHARPIN
may function in regulating general LFA-1 adhesiveness and
activation.
In migrating lymphocytes, adhesive cell-substrate contacts
need to be disengaged at the trailing edge to allow net forward
movement of the cell (Smith et al., 2005). We showed that in
migrating cells SHARPIN preferentially redistributes to uropods,
to which inactive LFA-1 is recruited (Morin et al., 2008; Smith
et al., 2005). The effects of SHARPIN on lymphocyte migration
were dependent on the ligand concentration. Increased LFA-1
activation in the absence of SHARPIN enhanced cell migration
on low ICAM-1 concentration and inhibited migration on high
ICAM-1 concentration and in transmigration assays. Similarly,
constitutively active LFA-1 mutant T cells (lacking the cyto-
plasmic domain) adhere better to ICAM-1 but show impaired
transendothelial migration in vitro and migrate worse to tissues
in vivo than wild-type cells (Lu and Springer, 1997; Semmrich
et al., 2005). A small-molecule agonist of LFA-1 also enhances
ligand binding and inhibits transendothelial migration of
lymphocytes accompanied by uropod elongation and impaired
de-adhesion (Yang et al., 2006). Also, T cells carrying a constitu-
tively active mutant (an engineered point mutation in the extra-
cellular domain) adhere better to ICAM-1 and yet home worse
than wild-type cells to PLN and MLN in vivo (Park et al., 2010).
These data strongly implicate the role of LFA-1 activity regulation
also in in vivo homing, although the contribution of slight changes
in the LFA-1 expression levels was not formally excluded. In fact,
LFA-1-dependent uropod elongation has very recently been
proposed to be a final common step during transendothelial
migration (Hyun et al., 2012). Therefore, a release mechanism
is needed before the cell can migrate further into the tissue,
and we postulate that SHARPIN, which is enriched in the uropod
of extravasating leukocytes, facilitates homing, and enhances
cell movement after transendothelial migration, could play an
important role in this process.
The results that SHARPIN-negative cells showed impaired
short-term (30 min–2 hr) homing to lymph nodes and yet
SHARPIN-deficient mice suffer from chronic inflammation may
have several explanations. The chronic inflammatory phenotype
develops during amuch longer time period (the first 4–6weeks of
postnatal life; HogenEsch et al., 1993), during which many other
LFA-1 mediated inflammatory functions apart from the initial
entry may become relevant. For instance, LFA-1-ICAM-1 inter-
action contributes to T cell costimulation (Wu¨lfing and Davis,
1998) and lymphocyte exit from the lymph nodes into lymphatic
vasculature (Reichardt et al., 2013), and therefore, dysregulatedCeLFA-1 activity in Sharpincpdm cells may modulate these pro-
cesses. Finally, in vivo SHARPIN-deficient cells localized better
thanwild-type cells to spleen (which is one of the affected organs
in Sharpincpdm mice), implicating that the contribution of LFA-1
activity regulation may vary in different organs.
Activation of LFA is essential for its function (Abram and
Lowell, 2009; Gahmberg et al., 2009; Hogg et al., 2011; Kinashi,
2007). LFA-1 is normally found in an inactive (i.e., incompetent
for ligand binding) form on leukocytes, and only after receiving
activation signals, does it become functionally competent.
Critical for the activation is the interaction of the cytoplasmic
domain of the b chain with talin and kindlins, which leads to
conformational changes of the extracellular domains in the
integrin heterodimer (Moser et al., 2009; Shattil et al., 2010).
LFA-1 activation can be indirectly inhibited through certain
signaling molecules, such as Cdc42, PIP5K1g90, cytokine
growth differentiation factor-15, and E3 ubiquitin ligase Cbl-b,
which interfere with the upstream activation signals (Bolomini-
Vittori et al., 2009; Hogg et al., 2011; Kinashi, 2007; Wernimont
et al., 2010; Zhang et al., 2003). In contrast, SHARPIN directly
binds to the cytosolic membrane proximal sequence of the
a-tail of LFA-1. Certain artificial deletions of the aL cytoplasmic
tail increase LFA-1 activity and cell adhesion to ICAM-1
(Lu and Springer, 1997; Semmrich et al., 2005). These mutants
are predicted to be unable to bind SHARPIN, which could
explain why these mutants are constitutively active.
Delineation of multiple functions and the physiological role of
SHARPIN remains an important area of future investigation. It
will be critical to determinate whether SHARPIN can simul-
taneously function as a component of the LUBAC complex and
an inhibitor of integrins, possibly implicating a role for linear
ubiquitination/NF-kB signaling in the regulation of integrin
signaling, or whether these two binding modes are mutually
exclusive. Moreover, we have shown that binding of SHARPIN
to the conserved segment of the a-cytoplasmic tails of collagen
and fibronectin-binding a2b1- and a5b1-integrins in cancer cells
prevents recruitment of the integrin activators talin and kindlin
with the b1-tail via a yet-unknown mechanism (Rantala et al.,
2011). Whether similar mechanisms operate in inhibition of
LFA-1 by SHARPIN remains to be determined, but also addi-
tional mechanisms could be involved. SHARPIN thus inhibits
both b1- and b2-integrins, although the activity regulation of
b1-integrins in adherent epithelial and mesenchymal cells is
fundamentally different from that of b2-integrins in professionally
motile leukocytes. Activity regulation of b1-integrins is modula-
tory, because these extracellular matrix receptors are always
at least partially active and strongly coupled to actin. In sharp
contrast, activation of b2-integrins needs to be fully switchable
from inactive to active within seconds to allow extravasation of
blood-borne leukocytes. In addition, many of the integrin activa-
tors are specific for b2-integrins over b1-integrins (e.g., the
guanosine triphosphatase Rap1 regulating LFA-1 vesicle traffic,
RAPL regulating LFA-1 transport, and adaptor 14-3-3 binding to
phosphorylated b2-integrin), and the Rap1-RAPL-dependent
LFA-1 activation involves binding to the alpha-subunit
cytoplasmic region of LFA-1 immediately adjacent to the
SHARPIN-binding site (Hogg et al., 2011; Katagiri et al., 2003).
This suggests that SHARPIN-mediated LFA-1 inactivation mayll Reports 5, 619–628, November 14, 2013 ª2013 The Authors 625
Figure 4. Sharpin Deactivates LFA-1, Improves Lymphocyte Extravasation, and Re-expression of SHARPIN Rescues the Uropod and
Migration Defects of SHARPIN-Deficient Cells
(A and B) Adhesion (A) and migration (B) of human PBMC transfected with SHARPIN siRNA or control siRNA on recombinant human ICAM-1 and the efficacy of
knockdown on SHARPIN protein levels.
(C) FACS analyses of the reporter mAb 24 and KIM127 cell surface binding to GFP-SHARPIN- and control (GFP only)-expressing, CXCL12-stimulated human
PBMC. The results are normalized against total CD11a expression.
(D) Cell-surface expression of 24 reporter epitope (normalized to total aL expression, left panel) and total aL expression (MFI, right panel) on wild-type and
Sharpincpdm MEFs expressing human LFA-1 was determined using FACS (a representative experiment).
(legend continued on next page)
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involve mechanisms that do not play a role in the regulation of
b1-integrins. However, this remains to be investigated in detail.
The specific physiological contribution of SHARPIN-mediated
NF-kb activation (via LUBAC) and integrin inactivation in different
lymphoid and nonlymphoid tissues and at different time points
also needs to be determined in the future using in vivo imaging,
specific inhibitors, and cell-type-specific conditional knockouts.
In conclusion, we have shown that SHARPIN preferentially
localizes to uropods in migrating lymphocytes, directly binds to
the cytoplasmic tail of aL-integrin, and keeps LFA-1 inactive in
these cells. Thereby, SHARPIN regulates uropod detachment
and locomotion and transendothelial migration of inflammatory
cells. Our findings challenge the prevailing dogma that the
inactive LFA-1 is the passive default form of the molecule by
showing that active interaction with endogenous SHARPIN is
required to maintain LFA-1 in the nonactivated state.
EXPERIMENTAL PROCEDURES
Mice, Cells, and Transfections
Spontaneously SHARPIN-deficient C57BL/KaLawRij-SHARPINcpdm/RijSunJ
(abbreviated Sharpincpdm) mice (HogenEsch et al., 1993; Seymour et al.,
2007) were maintained using heterozygote breedings. Sex-matched littermate
wild-type and Sharpincpdm animals (6–8 weeks) were used in all experiments.
The animal studies were approved by the Animal Experiment Board in Finland.
Mouse splenocytes and thymocytes were isolated usingmechanical teasing
and CD4+ T cells purified by negative selections. Human PBMC and mouse
lymphocytes were transfected with plasmids and siRNAs using human and
mouse T cell nucleofection kits (Amaxa).
Adhesion and Migration Assays and Uropod Analyses
Cells were allowed to adhere to precoated wells (5 mg/ml ICAM-1 or poly-
L-lysine), washed, fixed, stained with propidium iodide, and quantified with
Acumen Explorer laser scanner (TTP LabTech). For migration assays, cells
were imaged at 1 to 2 min intervals with or without CXCL12-stimulation on
ICAM-1 precoated (0.5–50 mg/ml) wells. Cell area, migration speed, and
path length analyses were done with National Institutes of Health (NIH) ImageJ
software. The extended uropods (uropod length >33% of cell body diameter)
and the duration of uropod attachment was scored from the time-lapse videos.
The polarization index of cells was calculated as the ratio of x to y, where x is
the longest distance across cells (from head to tail) and y is the greatest width
perpendicular to x.
Human and mouse leukocytes adhering or migrating on ICAM-1 were
stained for immunofluorescence using earlier-described protocols (Rantala(E) Representative FACS plots of the input population and transferred cells isol
experiments after 2 hr.Wild-type (indicated by blue arrow) andSharpincpdm (indica
the cells were costained with Alexa 647-labeled anti-CD4.
(F) Percentages of wild-type and Sharpincpdm CD4-positive and total lymphocy
recipient mice after a 2 hr recirculation period (n = 7 mice/genotype).
(G) Microscopic analyses of homing of wild-type (red) and Sharpincpdm (green)
venules are shown in gray. A representative micrograph and pooled data (n
represents 50 mm.
(H and I) Transmigration of human PBMC transfected with SHARPIN siRNA or
Expression of SHARPIN in a PBMC transmigrating through CD31+ endothelial
indicates the leukocyte uropod and the arrowhead the PBMC cell body below the
siRNA and n = 45 SHARPIN siRNA transfected cells from three independent exp
(J) Adhesion assays determining the binding of wild-type and Sharpincpdm splen
(PLL, a nonintegrin-binding ligand).
(K) Migration velocity of wild-type and Sharpincpdm splenocytes expressing GFP
(L) Uropod formation on Sharpincpdm cells expressing SHARPIN-GFP or GFP alo
Data are the mean ± SEM of three (A and I), two (B, G, and J–L), and two to five
denote p < 0.01, and triple asterisks denote p < 0.001 (two-tailed Student’s t tes
Ceet al., 2011). Migrating cells were stained with KIM127 and 24 using a 80 s
exposure of live cells before fixation (Smith et al., 2005). For FACS analysis,
cells were labeled using indirect or direct staining techniques and analyzed
using FACSCalibur with CellQuest software (BD Biosciences).
Immunoblottings, Immunoprecipitations, Pull-Downs, and Far-
Western Assays
Immunoblotting and immunoprecipitations were done as described (Mattila
et al., 2005). For the pull-down analysis, the cells were lysed or the recombi-
nant protein diluted in a 2% b-octylglucoside-containing lysis buffer,
incubated with 2.5 mM biotinylated integrin-peptides bound to streptavidin-
Sepharose beads, washed, and immunoblotted. For far-western assays, puri-
fied proteins were spotted on nitrocellulose membranes, incubated with
different GST-SHARPIN proteins in blocking buffer, washed, and detected
with GST antibody.
Statistical Analysis
The numerical data are presented asmean ± SEM. Each individual experiment
used cells from different persons or different mice. All statistical analyses were
performedwith two-tailed Student’s t test. p < 0.05was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, three movies, and one table and can be found with this article
online at http://dx.doi.org/10.1016/j.celrep.2013.10.011.
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